Harvard Bioscience (HBIO) Other Non-Current Assets (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Other Non-Current Assets data on file, last reported at $2.6 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $2.6 million, down 26.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 million (down 26.59% YoY), and the FY2025 annual result was $2.7 million, down 5.08% from the prior year.
• Other Non-Current Assets fell to $2.6 million in Q1 2026 per HBIO's latest filing, from $2.7 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $8.7 million in Q2 2022 and troughed at $2.3 million in Q3 2024.
• A 5-year average of $5.2 million and a median of $4.8 million in 2024 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets surged 1047.24% in 2022, then tumbled 69.39% in 2024.
• A 5-year view of Other Non-Current Assets shows it stood at $7.8 million in 2022, then fell by 16.8% to $6.5 million in 2023, then tumbled by 56.23% to $2.8 million in 2024, then dropped by 5.08% to $2.7 million in 2025, then fell by 3.98% to $2.6 million in 2026.
• Business Quant data shows HBIO's Other Non-Current Assets at $2.6 million in Q1 2026, $2.7 million in Q4 2025, and $3.8 million in Q3 2025.